Clinical trials: Hepatitis A
Hepatitis C Virus Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection
The primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with chronic genotype 1 or 2 HCV infection who are…
- Trial name
- NCT02613871
- Testing
- LDV/SOF
- Where
- 8 sites in Taiwan
- Volunteers
- 111 people
- Sponsor
- Gilead Sciences
Hepatitis C, Liver Transplantation
Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in Hepatitis C Virus (HCV) Positive Liver Transplant Patients
This is an exploratory study to evaluate the impact of eliminating steroid administration upon viral HCV load at 12 months measured by quantitative serum HCV-RNA determination in patients transplanted for HCV cirrhosis.
- Trial name
- CHASE (NCT00295607)
- Testing
- Tacrolimus, steroids, monoclonal anti-IL2R antibody
- Where
- 17 sites in Czechia, France and 6 more
- Volunteers
- 138 people
- Sponsor
- Astellas Pharma Inc
Hepatitis B, Liver Transplantation
HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection
The purpose of this study is to compare the use of HepeX-B versus HBIg, two anti-viral drugs, in patients who have received liver transplants due to liver failure caused by Hepatitis B infection.
- Trial name
- NCT00228592
- Testing
- HepeX-B, Hepatitis B Immune Globulin (HBIg)
- Where
- 20 sites in United States, France and 5 more
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Chronic Hepatitis C, Liver Fibrosis
Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)
The objective of the study is to evaluate the safety and efficacy of PEG-Intron versus no treatment for the prevention of fibrosis progression in adult participants with moderate to severe liver fibrosis secondary to chronic…
- Trial name
- NCT00049842
- Testing
- peginterferon alfa-2b (SCH 54031)
- Volunteers
- 540 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis B
An Study of Efficacy and Safety of Clevudine
Randomized, double blind parallel group, positive control, multi-center trial. Patients will be randomized at 1:1 ratio in group A or group B
- Trial name
- NCT01192854
- Testing
- Clevudine, Adefovir
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Eisai Co., Ltd.
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir (SOF)/velpatasvir (VEL; GS-5816) fixed-dose combination (FDC) for 12 weeks in participants with chronic…
- Trial name
- NCT02671500
- Testing
- SOF/VEL
- Where
- 38 sites in China, Malaysia and 3 more
- Volunteers
- 375 people
- Sponsor
- Gilead Sciences
Hepatitis B, Chronic
Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation
A phase 3, multicenter, open label study to assess the safety and efficacy of Nabi-HB, administered subcutaneously in patients with Hepatitis B Virus Associated Liver Disease who underwent liver transplantation.
- Trial name
- Nabi-HB-SC (NCT00800787)
- Testing
- Nabi-HB
- Sponsor
- Biotest Pharmaceuticals Corporation
Hepatitis C Virus
A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir
The purpose of this study is to evaluate the effectiveness of a simeprevir-containing hepatitis C virus (HCV) treatment regimen as measured by sustained virologic response (SVR).
- Trial name
- NCT02103699
- Testing
- No intervention
- Where
- 32 sites in United States
- Volunteers
- 315 people
- Sponsor
- Janssen Scientific Affairs, LLC
Chronic HCV Infection
Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C
The safety, tolerability and antiviral activity of Antaitavir Hasophate in Combination With Yiqibuvir in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) infection
- Trial name
- NCT05395416
- Testing
- HEC74647PA+HEC110114
- Where
- 36 sites in China
- Volunteers
- 514 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Hepatitis B, Chronic
A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
The purpose of this study is to evaluate the efficacy in terms of hepatitis B surface antigen (HBsAg) levels of the study intervention (that is, JNJ-73763989 + JNJ-56136379 + nucleos[t]ide analog [NA] and pegylated interferon…
- Trial name
- PENGUIN (NCT04667104)
- Testing
- JNJ-73763989, Tenofovir disoproxil, Tenofovir alafenamide (TAF)
- Where
- 11 sites in Japan, New Zealand and 2 more
- Volunteers
- 48 people
- Sponsor
- Janssen Research & Development, LLC
HCV Infection
Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment
The primary objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of voxilaprevir (formerly GS-9857) in participants with severe renal impairment and matched healthy control participants.
- Trial name
- NCT02402452
- Testing
- Voxilaprevir
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Hepatitis C
Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing
This non-interventional clinical study will be conducted to prospectively collect serial plasma and serum samples from treatment naïve subjects with chronic HCV infection who are initiating sofosbuvir-based therapy.
- Trial name
- NCT02068963
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 352 people
- Sponsor
- Hologic, Inc.
Diphtheria, Tetanus
Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants
This study will assess both the antibody persistence of the investigational vaccine and the immune response and safety of a booster dose of PENTAXIM™ vaccine in 18 months-old toddlers who participated in an earlier study in order…
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT00303316
- Testing
- DTaP-IPV//PRP~T combined vaccine
- Where
- Argentina
- Volunteers
- 458 people, healthy volunteers welcome
- Sponsor
- Sanofi
Acute-On-Chronic Liver Failure
TAK-242 in Patients With Acute Alcoholic Hepatitis
A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in subjects with acute decompensation of…
- Trial name
- NCT04620148
- Testing
- TAK-242
- Where
- 3 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- Akaza Bioscience Ltd
Haemophilus Influenzae Type b, Diphtheria
Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine
To assess the safety and reactogenicity of the DTPa-HBV-IPV/Hib vaccine and DTPa-IPV/Hib vaccine. This DTPa-IPV/Hib vaccine given at 3 and 4 months of age is co-administered with GSK Biologicals' rotavirus vaccine or Placebo.
- Conditions
- Haemophilus Influenzae Type b, Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT00325143
- Testing
- DTPa-HBV-IPV/Hib, DTPa-IPV/Hib vaccine
- Where
- 3 sites in Singapore
- Volunteers
- 702 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C
A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C
This dose-escalating study is to evaluate the efficacy and the safety of different doses of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA) and Ribavirin（RBV） in the…
- Trial name
- NCT01908335
- Testing
- PEG-IFN-SA /RBV low dose, PEG-IFN-SA /RBV middle dose, PEG-IFN-SA /RBV high dose
- Where
- 52 sites in China
- Volunteers
- 212 people
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
Hepatitis C
Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)
This is a study comparing grazoprevir (MK-5172) plus elbasvir (MK-8742) treatment with sofosbuvir (SOF) plus Pegylated Interferon plus Ribavirin (RBV) [PR] treatment in treatment-naïve and prior PR treatment failure participants…
- Trial name
- NCT02358044
- Testing
- Sofosbuvir, PegIntron, Ribavirin
- Volunteers
- 257 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis B
A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults
This study is designed to assess the relative bioavailability of ABI-H2158 tablets (Test Formulation) compared to ABI-H2158 tablets (Reference Formulation).
- Trial name
- NCT04083716
- Testing
- ABI-H2158 Reference Formulation, ABI-H2158 Test Formulation
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Pregnant
DV2-HBV-27: Observational Pregnancy Registry
Purpose of the study is to evaluate pregnancy outcomes among women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy
- Trial name
- HBV-27 (NCT03664648)
- Testing
- HEPLISAV-B
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Hepatitis B
Study on the Tolerance and Pharmacokinetics of GST-HG141 Tablets
To Evaluate the Tolerability and Pharmacokinetics of GST-HG141 Tablets in Single-center, Randomized, Double-blind, Placebo-controlled Multiple-dose, Single-dose, Multiple-dose Phase Ia Clinical Trials in Healthy Subjects .
- Trial name
- GST-HG141 (NCT04386915)
- Testing
- GST-HG141 tablets
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Fujian Cosunter Pharmaceutical Co. Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.